Head-to-head · Cost-Efficiency Index
Found vs REMEVi
Two GLP-1 programs on the bench, scored on the same six factors. Here's how their real cost of ownership compares — and which one we'd start with.
Found
Cost-first shoppers who also want behavior-change coaching bundled with the medication.
Visit FoundREMEVi
Cost-first shoppers who want spanish-speaking patients wanting bilingual, LegitScript-certified compounded GLP-1.
Visit REMEViThe verdict
Found takes it, leading the Cost-Efficiency Index 88 to 80. The cheapest identical price on both molecules nationwide — unbeatable raw cost-per-month, capped only by a coaching subscription you can't fully unbundle. REMEVi still earns a B− — Cost-first shoppers who want spanish-speaking patients wanting bilingual, LegitScript-certified compounded GLP-1.
Worth knowing either way: our overall #1 pick is CoreAge Rx (Cost-Efficiency Index 94/100 — the top of the board). See how it stacks up: CoreAge Rx vs Found.
Factor by factor
Both providers scored on our six Cost-Efficiency Index factors. The stronger side on each row is marked in teal.
Normalized Cost/Month
Price Transparency
Nationwide Access
Formulation Options
Clinical Oversight
Contract Flexibility
Pricing, coverage & formulary
The disclosed facts behind the scores. Lower price wins its row (teal).
| Spec | Found | REMEVi |
|---|---|---|
| Cost-Efficiency Index | 88/100 | 80/100 |
| Semaglutide / mo | $129/mo | $219/mo |
| Tirzepatide / mo | $129/mo | $319/mo |
| Semaglutide / yr (modeled) | $1,548 | $2,628 |
| Tirzepatide / yr (modeled) | $1,548 | $3,828 |
| Coverage | All 50 states | All 50 states |
| Oral / sublingual | No | Yes |
| Brand-name access | Compounded only | Compounded only |
| Rank on the board | #7 | #37 |
Found
88/100Where the value is
- Lowest cost-per-month on the board — identical $129 on both molecules
- Nationwide
- Strong behavior-change program adds value
The tradeoffs
- Coaching subscription can't be unbundled, which reduces contract flexibility
- Compounded only
REMEVi
80/100Where the value is
- A genuinely flat rate: 'the same price at every dose', stated as such, with no dose upcharge and no introductory rate to step off
- Longer terms are published openly rather than used as a teaser — semaglutide falls to $189 on 12 weeks and $149 on 52
- A daily oral semaglutide tablet is offered alongside the injection
The tradeoffs
- The flat rate is the highest entry price of the top-scoring programmes here; the cheaper $149 figure needs a full year
- No FDA-approved brand-name pathway — the Wegovy and Ozempic pages are comparison content, not products
Assume any provider we list may compensate us — we may earn a commission, at no cost to you. It never changes the Cost-Efficiency Index. Pricing, states and verification reflect each provider's public disclosures at last review; prices change — confirm on the provider's site. Not medical advice. See our disclosure.